298 related articles for article (PubMed ID: 32153047)
1. Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer.
Connell SP; O'Reilly E; Tuzova A; Webb M; Hurst R; Mills R; Zhao F; Bapat B; Cooper CS; Perry AS; Clark J; Brewer DS
Prostate; 2020 May; 80(7):547-558. PubMed ID: 32153047
[TBL] [Abstract][Full Text] [Related]
2. Integration of Urinary EN2 Protein & Cell-Free RNA Data in the Development of a Multivariable Risk Model for the Detection of Prostate Cancer Prior to Biopsy.
Connell SP; Mills R; Pandha H; Morgan R; Cooper CS; Clark J; Brewer DS; The Movember Gap Urine Biomarker Consortium
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925381
[TBL] [Abstract][Full Text] [Related]
3. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
4. Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance.
Zhao F; Olkhov-Mitsel E; van der Kwast T; Sykes J; Zdravic D; Venkateswaran V; Zlotta AR; Loblaw A; Fleshner NE; Klotz L; Vesprini D; Bapat B
J Urol; 2017 Feb; 197(2):335-341. PubMed ID: 27545574
[TBL] [Abstract][Full Text] [Related]
5. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
[TBL] [Abstract][Full Text] [Related]
6. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.
Zhao F; Olkhov-Mitsel E; Kamdar S; Jeyapala R; Garcia J; Hurst R; Hanna MY; Mills R; Tuzova AV; O'Reilly E; Kelly S; Cooper C; ; Brewer D; Perry AS; Clark J; Fleshner N; Bapat B
Clin Epigenetics; 2018 Nov; 10(1):147. PubMed ID: 30470249
[TBL] [Abstract][Full Text] [Related]
7. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
8. Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance.
Zhao F; Vesprini D; Liu RSC; Olkhov-Mitsel E; Klotz LH; Loblaw A; Liu SK; Bapat B
Urol Oncol; 2019 May; 37(5):297.e9-297.e17. PubMed ID: 30777394
[TBL] [Abstract][Full Text] [Related]
9. Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer.
Fujita K; Hayashi T; Matsuzaki K; Nakata W; Masuda M; Kawashima A; Ujike T; Nagahara A; Tsuchiya M; Kobayashi Y; Nojima S; Uemura M; Morii E; Miyoshi E; Nonomura N
Oncotarget; 2016 Aug; 7(35):56643-56649. PubMed ID: 27494861
[TBL] [Abstract][Full Text] [Related]
10. A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA.
Brikun I; Nusskern D; Decatus A; Harvey E; Li L; Freije D
Clin Epigenetics; 2018; 10():91. PubMed ID: 29988684
[TBL] [Abstract][Full Text] [Related]
11. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
Sanda MG; Feng Z; Howard DH; Tomlins SA; Sokoll LJ; Chan DW; Regan MM; Groskopf J; Chipman J; Patil DH; Salami SS; Scherr DS; Kagan J; Srivastava S; Thompson IM; Siddiqui J; Fan J; Joon AY; Bantis LE; Rubin MA; Chinnayian AM; Wei JT; ; Bidair M; Kibel A; Lin DW; Lotan Y; Partin A; Taneja S
JAMA Oncol; 2017 Aug; 3(8):1085-1093. PubMed ID: 28520829
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive Detection of High Grade Prostate Cancer by DNA Methylation Analysis of Urine Cells Captured by Microfiltration.
Larsen LK; Jakobsen JS; Abdul-Al A; Guldberg P
J Urol; 2018 Oct; 200(4):749-757. PubMed ID: 29702096
[TBL] [Abstract][Full Text] [Related]
13. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
14. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
[TBL] [Abstract][Full Text] [Related]
15. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
[TBL] [Abstract][Full Text] [Related]
16. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.
Donovan MJ; Noerholm M; Bentink S; Belzer S; Skog J; O'Neill V; Cochran JS; Brown GA
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):370-5. PubMed ID: 26345389
[TBL] [Abstract][Full Text] [Related]
17. Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging.
Bakavicius A; Daniunaite K; Zukauskaite K; Barisiene M; Jarmalaite S; Jankevicius F
Clin Epigenetics; 2019 Aug; 11(1):115. PubMed ID: 31383039
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of a novel urine-based gene fusion TTTY15-USP9Y in predicting prostate biopsy outcome.
Zhu Y; Ren S; Jing T; Cai X; Liu Y; Wang F; Zhang W; Shi X; Chen R; Shen J; Lu J; Xu C; Wang H; Wang H; Wang Y; Liu B; Li Y; Fang Z; Guo F; Qiao M; Shen D; Lu X; Gao X; Hou J; Sun Y
Urol Oncol; 2015 Sep; 33(9):384.e9-20. PubMed ID: 26008593
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.
Johnson H; Guo J; Zhang X; Zhang H; Simoulis A; Wu AHB; Xia T; Li F; Tan W; Johnson A; Dizeyi N; Abrahamsson PA; Kenner L; Feng X; Zou C; Xiao K; Persson JL; Chen L
BMC Med; 2020 Dec; 18(1):376. PubMed ID: 33256740
[TBL] [Abstract][Full Text] [Related]
20. A urine-based methylation signature for risk stratification within low-risk prostate cancer.
Jatkoe TA; Karnes RJ; Freedland SJ; Wang Y; Le A; Baden J
Br J Cancer; 2015 Mar; 112(5):802-8. PubMed ID: 25695483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
